Figure S4. Kaplan-Meier overall survival curves in patients who did and did not have long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury. (TIF 49723 kb
Comparison of prognostic factors according to the numbers of peptide-specific responses (n = 36 HLA-...
Figure S1. Kaplan-Meier curves for overall survival in patients stratified for the occurrence of dru...
Figure S1. Kaplan-Meier diagrams showing PFS (A) and OS (B) for subgroups according to the occurrenc...
Figure S6. Kaplan-Meier overall survival curves in patients who did and did not have symptoms of pan...
Figure S5. Kaplan-Meier overall survival curves in patients who did and did not receive steroids for...
Figure S3. Kaplan-Meier overall survival curves in patients who resumed and discontinued immune chec...
Figure S2B. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by t...
Table S1. Patient clinical characteristics by type of immune checkpoint inhibitor therapy. Table S2....
Figure S2A. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by c...
Figure S1. Computed tomography findings of ICIPI. (A) Images from a patient with pancreatic metastas...
Table S1. Characteristics of patients by typicality of cholecystitis symptoms. Table S2. Characteris...
S1: baseline characteristics stratified by adverse events. S2-S3: Kaplan-Meier curves for OS and PFS...
Figures S5 to S7 Global immune-related adverse events (irAEs) with ipilimumab all dosage, 3 mg/kg, a...
Table S1. Effect of steroid treatment duration and timing to SIT initiation after IMC onset. Figure ...
Appendix 6. Cases of Immune Checkpoint Inhibitor-Induced Endocrinopathies â Primary Adrenal Insuff...
Comparison of prognostic factors according to the numbers of peptide-specific responses (n = 36 HLA-...
Figure S1. Kaplan-Meier curves for overall survival in patients stratified for the occurrence of dru...
Figure S1. Kaplan-Meier diagrams showing PFS (A) and OS (B) for subgroups according to the occurrenc...
Figure S6. Kaplan-Meier overall survival curves in patients who did and did not have symptoms of pan...
Figure S5. Kaplan-Meier overall survival curves in patients who did and did not receive steroids for...
Figure S3. Kaplan-Meier overall survival curves in patients who resumed and discontinued immune chec...
Figure S2B. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by t...
Table S1. Patient clinical characteristics by type of immune checkpoint inhibitor therapy. Table S2....
Figure S2A. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by c...
Figure S1. Computed tomography findings of ICIPI. (A) Images from a patient with pancreatic metastas...
Table S1. Characteristics of patients by typicality of cholecystitis symptoms. Table S2. Characteris...
S1: baseline characteristics stratified by adverse events. S2-S3: Kaplan-Meier curves for OS and PFS...
Figures S5 to S7 Global immune-related adverse events (irAEs) with ipilimumab all dosage, 3 mg/kg, a...
Table S1. Effect of steroid treatment duration and timing to SIT initiation after IMC onset. Figure ...
Appendix 6. Cases of Immune Checkpoint Inhibitor-Induced Endocrinopathies â Primary Adrenal Insuff...
Comparison of prognostic factors according to the numbers of peptide-specific responses (n = 36 HLA-...
Figure S1. Kaplan-Meier curves for overall survival in patients stratified for the occurrence of dru...
Figure S1. Kaplan-Meier diagrams showing PFS (A) and OS (B) for subgroups according to the occurrenc...